Understanding TAFINLAR + MEKINIST

NSCLC Treatment Option

How does TAFINLAR + MEKINIST treat NSCLC?

TAFINLAR and MEKINIST are prescription medicines that can be used in combination to treat a type of lung cancer called non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic NSCLC), and that has a certain type of abnormal “BRAF V600E” gene. TAFINLAR, in combination with MEKINIST, is not for use in treating people with wild-type BRAF NSCLC.

 

The first and only FDA-approved targeted treatment for BRAF V600E metastatic NSCLC

TAFINLAR + MEKINIST are prescription medicines used in combination and is the first and only FDA-approved targeted treatment option for your BRAF V600E metastatic NSCLC.

Could TAFINLAR + MEKINIST be right for you?

Your health care provider will perform a biomarker test to make sure that TAFINLAR, in combination with MEKINIST, is right for you.

It is not known if TAFINLAR with MEKINIST is safe and effective in children younger than 6 years of age.

Before starting NSCLC treatment

It is important to keep an open dialogue with your health care provider. Tell your health care provider about all of your medical conditions, including if you:


  • Have had bleeding problems or blood clots
  • Have stomach problems
  • Have inflammation of the colon
  • Have heart problems
  • Have eye problems
  • Have lung or breathing problems
  • Have high blood pressure (hypertension)
  • Have liver or kidney problems
  • Have diabetes
  • Plan to have surgery, dental, or other medical procedures
  • Have a deficiency of the glucose-6-phosphate dehydrogenase (G6PD) enzyme
  • Are pregnant or plan to become pregnant. TAFINLAR and MEKINIST can harm your unborn baby
  • Are breastfeeding or plan to breastfeed. It is not known if TAFINLAR and/or MEKINIST passes into your breast milk